cabotegravir (Apretude)
Jump to navigation
Jump to search
Indications
- treatment of HIV1 infection
- for use in combination with rilpivirine (IM) orabacavir-lamivudine (PO)
- pre-exposure HIV1 prophylaxis
Dosage
- long-acting cabotegravir plus rilpivirine every 4 weeks (2 injections) or 8 weeks (3 injections) IM[1][2]
Injection: 200 mg/mL
Monitor
Mechanism of action
More general terms
Component of
References
- ↑ 1.0 1.1 Margolis DA, Gonzalez-Garcia J, Stellbrink HJ et al Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. July 24, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28750935 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31917-7/fulltext
Boyd MA, Cooper DA Long-acting injectable ART: next revolution in HIV? Lancet. July 24, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28750936 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31962-1/fulltext
FDA News Release. Jan 21, 2021 FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV. https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv - ↑ 2.0 2.1 Saag MS, Gandhi RT, Hoy JF, et al Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. Published online October 14, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33052386 https://jamanetwork.com/journals/jama/fullarticle/2771873
Gandhi RT, Bedimo R, Hoy JF et al Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2022 Recommendations of the International Antiviral Society - USA Panel. JAMA. Published online December 1, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36454551 https://jamanetwork.com/journals/jama/fullarticle/2799240